June 11 (Reuters) - Sage Therapeutics said on Tuesday its experimental drug met the main goal of a mid-stage study in patients with a type of rare disease known as Huntington's disease. (Reporting by Sriparna Roy in Bengaluru; Editing by Shailesh Kuber)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
10.7 USD | -1.34% | -0.37% | -50.95% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-50.95% | 652M | |
+16.59% | 122B | |
+19.35% | 115B | |
+21.22% | 26.64B | |
-23.73% | 19.91B | |
-17.47% | 16.32B | |
-45.95% | 15.52B | |
-18.31% | 15.49B | |
+63.94% | 14.83B | |
+2.03% | 13.67B |
- Stock Market
- Equities
- SAGE Stock
- News Sage Therapeutics, Inc.
- Sage Therapeutics' rare disease drug meets main goal in mid-stage study